Trial intelligence / Profile preview

Open-label extension study of lacosamide (Vimpat) as adjunctive therapy for partial-onset seizures

2014-004384-21Phase 3

Sponsor
UCB
Start
Mar 2015
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, open-label, single-arm trial of lacosamide in epilepsy and Focal Onset Epilepsy, sponsored by UCB. Primary endpoint: Number of subjects with at least one adverse event.

02

Drugs

lacosamide
03

Conditions

epilepsyFocal Onset Epilepsy

Beyond the preview

Go deeper on 2014-004384-21.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2014-004384-21.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call